Vivani Medical (VANI) Expected to Announce Quarterly Earnings on Monday

Vivani Medical (NASDAQ:VANI) will likely be announcing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Monday, March 31st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect Vivani Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vivani Medical Stock Up 1.5 %

VANI stock opened at $1.04 on Friday. The stock has a market capitalization of $61.32 million, a price-to-earnings ratio of -2.30 and a beta of 2.81. Vivani Medical has a 52-week low of $0.91 and a 52-week high of $2.09. The stock’s fifty day simple moving average is $1.05 and its 200-day simple moving average is $1.17.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Vivani Medical in a report on Wednesday, April 16th.

Insiders Place Their Bets

In other Vivani Medical news, Director Gregg Williams acquired 44,400 shares of the firm’s stock in a transaction on Monday, April 7th. The stock was bought at an average cost of $0.99 per share, for a total transaction of $43,956.00. Following the completion of the purchase, the director now directly owns 4,799,200 shares in the company, valued at $4,751,208. This represents a 0.93 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased a total of 108,922 shares of company stock valued at $108,769 over the last quarter. Company insiders own 44.30% of the company’s stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.